Payer Insights Survey: Gathering Early Perceptions of Health Plan Response to the Inflation Reduction Act of 2022
AMCP Spring 2024 Silver Poster.
Gauging how healthcare payers and pharmaceutical manufacturers are reacting to the Inflation Reduction Act of 2022
Magnolia engaged pharmacy directors, medical directors, and actuaries at health plans and PBMs to understand how payers are designing their plan offerings and adjusting their formularies in the coming years.
Gathering early perceptions of payer response to the Inflation Reduction Act of 2022
Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.
Gathering early perceptions of payer response to the Inflation Reduction Act of 2022: Medicare Part D Redesign
Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.
Enhancing Oncology Model (EOM) Fact Sheet
Download to see features of the new healthcare delivery model and value-based care payment system for oncology practices, administered by the Centers for Medicare and Medicaid Services (CMS).
Enhancing Oncology Model (EOM) White Paper: Perspectives from Oncology Practices and the Path Forward in Value-Based Care
To gather early perceptions of the EOM and understand how oncology practices evaluated participation decisions in the new model, Magnolia facilitated an advisory panel discussion with key opinion leaders.
Developing strategic game plans in response to shifts in federal policy
Biopharmaceutical companies engaged Magnolia to help them understand the implications of the Inflation Reduction Act of 2022 and develop long-term strategic plans to adjust for the sweeping market changes it will cause.
Launch planning in an ever-evolving policy and regulatory landscape
A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies.
Developing the appropriate regulatory strategy for a patient-centric, therapy-agnostic app
A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease.
FY24 Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital Prospective Payment System (LTCH) Proposed Rule
Download to see features of the proposed rule.